Medtronic (NYSE:MDT) said it asked the FDA for an expanded indication for its Guardian Sensor 3 device that would open the glucose sensor up for Medicare reimbursement.

The Fridley, Minn.-based medtech titan said it filed for pre-market approval of non-adjunctive labeling for Guardian Sensor 3 for use with its MiniMed 670G insulin management system. If granted, the PMA would indicate that the device is accurate enough to calculate meal-based insulin doses and correct high glucose levels, Medtronic said.

Get the full story at our sister site, Drug Delivery Business News